Arecor Therapeutics plc
(“Arecor” or the “Group”)

ARECOR TO COLLABORATE WITH TOP 10 GLOBAL PHARMACEUTICAL COMPANY

Arecor expands its global partnerships through collaboration to develop an enhanced antibody formulation

Cambridge, UK, 17 August 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces that it has signed an agreement with a top 10 pharmaceutical company to develop an enhanced antibody formulation for one of its investigational drugs.

Under the terms of this agreement, Arecor will use its proprietary formulation technology platform, Arestat™, to develop a novel, stable formulation of a liquid, high concentration antibody. The collaborator will fund the development work, generating new revenue for Arecor. This agreement adds to Arecor’s growing portfolio of partnerships.

Sarah Howell, Chief Executive Officer of Arecor, said: “This collaborator is a leader in the development of novel medicines. Arecor has a proven track record of leveraging its Arestat technology to help deliver these complex therapeutics. We work closely with our partners to develop more effective treatments where superior properties bring even greater benefit to patients and we look forward to working with the world-renowned R&D team.”

This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 (“UK MAR”).

-ENDS-

For more information, please contact:
Arecor Therapeutics plc www.arecor.com

Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com

Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com

Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com

Panmure Gordon (UK) Limited (NOMAD and Broker)
Freddy Crossley, Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking) Tel: +44 (0) 20 7886 2500

Consilium Strategic Communications
Chris Gardner, David Daley, Lindsey Neville Tel: +44 (0) 20 3709 5700
Email: arecor@consilium-comms.com

Notes to Editors

About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.

For further details please see our website, www.arecor.com